Home Cart Sign in  
Chemical Structure| 19171-19-8 Chemical Structure| 19171-19-8

Structure of Pomalidomide
CAS No.: 19171-19-8

Chemical Structure| 19171-19-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pomalidomide, a third-generation immunomodulatory agent, acts as molecular glue by interacting with the E3 ligase cereblon and inducing the degradation of essential Ikaros transcription factors.

Synonyms: CC-4047; 3-amino Thalidomide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pomalidomide

CAS No. :19171-19-8
Formula : C13H11N3O4
M.W : 273.24
SMILES Code : NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
Synonyms :
CC-4047; 3-amino Thalidomide
MDL No. :MFCD12756407

Safety of Pomalidomide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H361
Precautionary Statements:P501-P202-P201-P280-P308+P313-P405

Isoform Comparison

Biological Activity

Target
  • TNF-α

    TNF-α, IC50:13 nM

  • CRBN

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.66mL

0.73mL

0.37mL

18.30mL

3.66mL

1.83mL

36.60mL

7.32mL

3.66mL

References

[1]Li Z, Qiu Y, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8(8):e71754.

[2]Ocio EM, Fernández-Lázaro D, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015 Mar;29(3):705-14.

[3]Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014 Jan 17;343(6168):305-9. doi: 10.1126/science.1244917. Epub 2013 Nov 29. PMID: 24292623; PMCID: PMC4070318.

[4]Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. Erratum in: Leukemia. 2012 Nov;26(11):2445. PMID: 22552008; PMCID: PMC3496085.

[5]Moutouh-de Parseval LA, Verhelle D, Glezer E, Jensen-Pergakes K, Ferguson GD, Corral LG, Morris CL, Muller G, Brady H, Chan K. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest. 2008 Jan;118(1):248-58. doi: 10.1172/JCI32322. PMID: 18064299; PMCID: PMC2117764.

[6]Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984-92. doi: 10.1158/1078-0432.CCR-05-0577. PMID: 16115943.

 

Historical Records

Categories